Genpact to acquire life sciences regulatory services firm Pharmalink

Genpact Ltd, a global leader in transforming and running business processes and operations, yesterday announced it had signed a definitive agreement to acquire Pharmalink Consulting, a leading global provider of regulatory services to the life sciences industry for more than 15 years.

The acquisition will complement Genpact's portfolio of services in the Life Sciences vertical and add significant consulting, outsourcing and operations capabilities.

It also significantly expands Genpact's capabilities in supporting the life sciences research and development functions, including regulatory strategy, filing submissions, complex compliance services and the management of post-licensing activities.

Pharmalink's specialised domain expertise, speed, responsiveness and ability to scale have made it a leading provider for sustainable outsourcing of regulatory affairs services.

Its clients include nearly all of the 20 largest global life sciences companies.

Pharmalink provides end-to-end regulatory services including strategy, chemistry manufacturing & controls (CMC), regulatory operations and publishing &technology services.

''This acquisition fits in exactly with our strategy to invest in solutions in specific growth areas in specific verticals such as Life Sciences,'' said NV 'Tiger' Tyagarajan, president and CEO, Genpact.  ''In an industry that's undergoing intense transformation, adding Pharmalink's combination of talent, process expertise and domain knowledge to Genpact's portfolio will allow us to better serve our life sciences clients.''

''Genpact will bring the global scale, process excellence, analytical insights and technology needed to further enhance our outsourcing services offering demanded by the market,'' said Peter Griffin, chairman, Pharmalink Consulting. 

''This combination will allow us to deliver more end-to-end regulatory affairs solutions based on Genpact's proprietary Smart Enterprise Processes SEPSM methodology.''

Gary Charbonneau, vice president of Global Regulatory Affairs at Allergan adds, ''The combination of Genpact and Pharmalink is very exciting not just for me as a client, but for the industry at large. To have the deep experience and reputation of Pharmalink within the Regulatory Affairs arena allied to the scale and process excellence of Genpact is a compelling proposition.''

As part of the transaction, Pharmalink's employees based in the US, the UK, India, Ireland and Puerto Rico will become part of Genpact's Life Sciences vertical.